AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06379191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition intervention model based on WeChat applets
Description: We recorded the full nutritional management plan for ovarian cancer chemotherapy patients obtained through evidence-based in the previous period into the applet developed by our team - Good Nutrition. At the first chemotherapy admission assessment, patients were instructed to search for the applet on WeChat and add it to My applet. The patient was introduced to the main functional sections of the applet and the content settings for each section. The patient was instructed to turn on the applet notification permission and set it to receive new content alerts. Patients were invited to join our nutrition management group chat. They were informed that throughout the intervention phase, we would be sending evidence-based scientific articles to the group chat for independent study, and that they were allowed to ask questions, share personal experiences, and discuss lifestyles within the group.
Study NCT06379191 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition intervention model based on WeChat applets
Description: We recorded the full nutritional management plan for ovarian cancer chemotherapy patients obtained through evidence-based in the previous period into the applet developed by our team - Good Nutrition. At the first chemotherapy admission assessment, patients were instructed to search for the applet on WeChat and add it to My applet. The patient was introduced to the main functional sections of the applet and the content settings for each section. The patient was instructed to turn on the applet notification permission and set it to receive new content alerts. Patients were invited to join our nutrition management group chat. They were informed that throughout the intervention phase, we would be sending evidence-based scientific articles to the group chat for independent study, and that they were allowed to ask questions, share personal experiences, and discuss lifestyles within the group.
Study NCT05725252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2203
Description: NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
Study NCT05725252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R
Description: administration of active comparator
Study NCT06521164 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Haermonics Pure system
Description: pericardial flushing with Haermonics Pure system
Study NCT06063798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia for laryngotracheal surgery
Description: Patients undergoing general anesthesia and mechanical ventilation.
Study NCT05698511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
Study NCT06684184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: The initial dose is 9 µ g, administered intravenously continuously for 5 days, with a total dose of 38.5 µ g. After stopping the medication for one week, the patient received a second infusion of Blinatumomab for a total of 5 days, with a total dose of 38.5 µ g.
Study NCT06683144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure feedback
Description: * Determining the actual SHS exposure risk level and providing feedback.~* Determining the urinary cotinine test result and providing feedback.~* Feedback on the consistency or difference between the perceived SHS exposure risk level and the actual SHS exposure risk level.
Study NCT06063798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia for laryngotracheal surgery
Description: Patients undergoing general anesthesia and mechanical ventilation.
Study NCT06063798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation by FCV
Description: Mechanical ventilation is assured by Flow-controlled ventilation mode.
Study NCT06683144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive education
Description: Slide presentation, video presentation, Q\&A, evaluation of learning and discussion of results
Study NCT06683144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media post
Description: Sharing informational materials such as messages, brochures, and videos related to SHS exposure, including ways to protect yourself from SHS exposure and the adverse health effects of SHS exposure.
Study NCT06683066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprorelin for injection
Description: Specification: Triprorelin for injection 3.75mg. Produced and supplied by Qilu Pharmaceutical Co.
Study NCT06683066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphereline
Description: Specification: Diphereline 3.75mg. Produced by Ipsen Pharma Biotech and supplied by Qilu Pharmaceutical Co.
Study NCT06685328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal posterior pole vitrectomy combined with a sodium hyaluronate gel-covered internal limiting membrane(ILM) flap with balanced saline filling and postoperative supine position
Description: Vitrectomy of the posterior pole within the vascular arch was performed by a standard 25G ciliary flattening three-way tract procedure, followed by injection of a small amount of tretinoin suspension (TA) to mark the posterior vitreous cortex, which was excised. The inner limiting membrane (ILM) of the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the ILM around the hole was peeled off, leaving a semicircular piece of ILM attached to the hole, and then the single ILM flap was folded and covered with MH. 0.2 to 0.3 mL of hyaluronic acid gel (Bausch \& Lomb, Iviz) was injected over the inverted ILM flap using perfluorocarbon liquid for complete coverage. The perfluorocarbon liquid was aspirated. Postoperatively, the patient was advised to remain in a non-emergent supine position for 24 hours.
Study NCT06685328 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional vitrectomy combined with inner limiting membrane flap flip coverage with sterile air filling and postoperative prone position
Description: A standard 25G ciliary flattening three-way tract procedure was taken to perform posterior and midperipheral vitrectomy, followed by injection of a small amount of tretinoin (TA) to label the posterior vitreous cortex and excision of the posterior vitreous cortex within the vascular arch. The ILM on the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the peripapillary ILM was peeled off with forceps, leaving a semicircular piece of ILM attached to the foramen ovale, and the individual ILM flaps were then turned over and covered with MH. Air-liquid exchange was then performed and subsequent surgery was routinely performed according to existing surgical concepts. Ultrasonic emulsification and IOL implantation were selectively performed depending on the extent of the cataract and the patient's surgical needs. Antibiotic ointment is applied at the end of the procedure. After surgery, patients were advised to remain in strict prone position for 3 days.
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYHA1813
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SG001
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB1801
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: In accordance with the protocol
Study NCT06114511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: In accordance with the protocol
Study NCT06063798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation by HFJV
Description: Mechanical ventilation is assured by High frequency jet ventilation mode.
Study NCT05578950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: 100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
Study NCT05578950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbinafine
Description: one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
Study NCT05259787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation Etomidate combined with propofol
Description: Drug IV within 10 second during anesthesia induction.
Study NCT05259787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation Propofol
Description: Drug IV within 10 second during anesthesia induction.
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: In accordance with the protocol
Study NCT05227755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein isolate
Description: Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
Study NCT05227755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
Study NCT05863130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198 (C-14) (approach 1)
Description: BI 764198 (C-14) (approach 1)
Study NCT05863130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198 (C-14) (approach 2)
Description: BI 764198 (C-14) (approach 2)
Study NCT05797064 — intervention group
Intervention type: PROCEDURE
Intervention: Natural Orifice Specimen Extraction Surgery
Description: Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
Study NCT04859725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging with Snapscan camera
Description: Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
Study NCT05721144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Gas
Description: Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: In accordance with the protocol
Study NCT06682611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: In accordance with the protocol
Study NCT04690270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan 100 mg
Description: Single dose Sumatriptan 100 mg
Study NCT04690270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Description: Single dose Sumatriptan 100 mg
Study NCT06684145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape application
Description: Kinesiotape application will be performed by a certified researcher using 5cm x 5cm kinesiotape material. The standing patient, prepared in terms of clothing and skin, will be asked to lean forward. While adhering the tape to the right paravertebral region, the lower end of the tape will be adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. The patient, still leaning forward, will be then asked to make a slight rotation to the left; in this position, the tape will be adhered upwards on the paravertebral muscles without any tension. For the left paravertebral region, the procedure will be reversed as compared to the right, ensuring that the tape was not stretched at all.
Study NCT06684145 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Patients will be given a 30-day home exercise program. This consists of passive lumbar flexion (single and double leg stretching), hamstring stretching, pelvic tilt, half sit-up, bridge, straight leg raises, and hip and back extensor strengthening exercises.
Study NCT06684756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery
Description: Flexible optic devices and lasers fragment kidney stones during this operation. In this surgery, an ureteral access sheath is recommended to be used.
Study NCT06684756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery
Description: Flexible optic devices and lasers fragment kidney stones during this operation. In this surgery, an ureteral access sheath is recommended to be used.
Study NCT06684600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib + Pyrotinib
Description: Dalpiciclib Isethionate tablets, 125mg, oral administration on days 1 to 21, followed by a 7-day drug holiday, every 4 weeks; Pyrotinib Maleate tablets, 320mg, oral administration once daily on days 1 to 28, every 4 weeks; Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, or the investigator determines that the subject should discontinue study treatment.
Study NCT06682403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Received cable lock as default
Description: Participants will receive a cable lock as the default safety device option after filling out the survey. If the participant took a cable lock during their hospital visit and noted this in the survey, they will not be shipped a cable lock. If participants did not take a cable lock and noted this in the survey, they will be shipped a cable lock.
Study NCT06682403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice between cable lock or lock box
Description: Participant will have the option to select a lock box or cable lock shipped to their address after filling out the study survey.
Study NCT06685497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application follow-up
Description: Colorectal cancer patients enrolled in the 'Internet Plus' post-treatment management platform use the digital medical quality management system based on the 'COLORECTUM+' model for quality evaluation and continuous improvement. The platform integrates AI, using natural language processing and machine learning to analyze patient-reported symptoms, automatically assess severity, and generate alerts. Alerts are classified as yellow, orange, or red. Yellow indicates mild issues with self-care recommendations; consecutive yellow alerts prompt doctor contact within 24 hours. Orange indicates moderate severity, requiring doctor intervention within 24 hours. Red alerts signify serious symptoms or high-risk medication errors, prompting immediate notification of the doctor and emergency team. The system monitors symptom changes and updates alerts to support treatment optimization.
Study NCT06513663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands.~All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session.
Study NCT05250102 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse oximeter sensors
Description: Pulse oximeter reading will be compared to CO-oximeter reading.
Study NCT05852548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Mediated Intervention
Description: Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
Study NCT05786469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veltassa Oral Powder Product
Description: The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient
Study NCT05786469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient
Study NCT05017311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
Study NCT05017311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
Study NCT05017311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.